BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36332446)

  • 1. Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.
    Wu B; Shen L; Peng G; Li Y; Zhou Z; Li J; Huang X; Zhou Q; Jiang H; Huang J; Ding Q; Zhang Z; Qin Y; Hong X; Shi L; Zou Z; Yao J; Zhang J; Liu D; Wan C; Wu G; Song L; Chen S; Yi J; Yang K
    Oral Oncol; 2022 Dec; 135():106218. PubMed ID: 36332446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Mutations Activate the NF-κB Pathway to Promote Recurrence of Nasopharyngeal Carcinoma.
    You R; Liu YP; Lin DC; Li Q; Yu T; Zou X; Lin M; Zhang XL; He GP; Yang Q; Zhang YN; Xie YL; Jiang R; Wu CY; Zhang C; Cui C; Wang JQ; Wang Y; Zhuang AH; Guo GF; Hua YJ; Sun R; Yun JP; Zuo ZX; Liu ZX; Zhu XF; Kang TB; Qian CN; Mai HQ; Sun Y; Zeng MS; Feng L; Zeng YX; Chen MY
    Cancer Res; 2019 Dec; 79(23):5930-5943. PubMed ID: 31484669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole exome sequencing and transcriptome-wide profiling identify potentially subtype-relevant genes of nasopharyngeal carcinoma.
    Liu J; Li X; Yang S; Mou J; Lu H
    Pathol Res Pract; 2020 Dec; 216(12):153244. PubMed ID: 33113455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-Exome Sequencing of Nasopharyngeal Carcinoma Families Reveals Novel Variants Potentially Involved in Nasopharyngeal Carcinoma.
    Yu G; Hsu WL; Coghill AE; Yu KJ; Wang CP; Lou PJ; Liu Z; Jones K; Vogt A; Wang M; Mbulaiteye SM; Chen HH; Boland J; Yeager M; Diehl SR; Chen CJ; Hildesheim A; Goldstein AM
    Sci Rep; 2019 Jul; 9(1):9916. PubMed ID: 31289279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma.
    Dai W; Zheng H; Cheung AK; Tang CS; Ko JM; Wong BW; Leong MM; Sham PC; Cheung F; Kwong DL; Ngan RK; Ng WT; Yau CC; Pan J; Peng X; Tung S; Zhang Z; Ji M; Chiang AK; Lee AW; Lee VH; Lam KO; Au KH; Cheng HC; Yiu HH; Lung ML
    Proc Natl Acad Sci U S A; 2016 Mar; 113(12):3317-22. PubMed ID: 26951679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
    Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
    BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    Dai W; Chung DL; Chow LK; Yu VZ; Lei LC; Leong MM; Chan CK; Ko JM; Lung ML
    Clin Cancer Res; 2020 Dec; 26(24):6494-6504. PubMed ID: 32988965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
    Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
    J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma.
    Sasaki MM; Skol AD; Bao R; Rhodes LV; Chambers R; Vokes EE; Cohen EE; Onel K
    Cancer Epidemiol Biomarkers Prev; 2015 Aug; 24(8):1222-8. PubMed ID: 26014803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
    Cao Y; Chan KI; Xiao G; Chen Y; Qiu X; Hao H; Mak SC; Lin T
    BMC Cancer; 2019 Oct; 19(1):1022. PubMed ID: 31664962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
    Sahinli H; Akyürek N; Yılmaz M; Kandemir O; Duran AO; Kulaçoǧlu S; Uçar G; Acar E; Özet A; Öksüzoǧlu OBÇ; Özdemir NY
    J Cancer Res Ther; 2020 Dec; 16(Supplement):S43-S47. PubMed ID: 33380650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers to assess short-term disease local recurrence in nasopharyngeal carcinoma.
    Xu T; Su B; Wang C; Wang S; Huang H; Pan Y; Wang D; Wei W; Claret FX; Yang H
    Oncol Rep; 2015 Mar; 33(3):1418-26. PubMed ID: 25607111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast Europe.
    Fountzilas G; Psyrri A; Giannoulatou E; Tikas I; Manousou K; Rontogianni D; Ciuleanu E; Ciuleanu T; Resiga L; Zaramboukas T; Papadopoulou K; Bobos M; Chrisafi S; Tsolaki E; Markou K; Giotakis E; Koutras A; Psoma E; Kalogera-Fountzila A; Skondra M; Bamia C; Pectasides D; Kotoula V
    Int J Cancer; 2018 Jan; 142(1):66-80. PubMed ID: 28857155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protein microarray analysis on changes in protein phosphorylation in recurrent nasopharyngeal carcinoma].
    Su HF; Zhang XB; Fang M; He QC; Li WF; Wu SX
    Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3219-22. PubMed ID: 22333108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copy number loss in granzyme genes confers resistance to immune checkpoint inhibitor in nasopharyngeal carcinoma.
    Ma Y; Chen X; Wang A; Zhao H; Lin Q; Bao H; Zhang Y; Hong S; Tang W; Huang Y; Yang Y; Wu X; Shao Y; Fang W; Zhang L
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of succinate dehydrogenase subunit B and up-regulation of pyruvate dehydrogenase kinase 1 predicts poor prognosis in recurrent nasopharyngeal carcinoma.
    Dai Z; Pan S; Chen C; Cao L; Li X; Chen X; Su X; Lin S
    Tumour Biol; 2016 Apr; 37(4):5145-52. PubMed ID: 26547584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
    Fei Z; Deng Z; Zhou L; Li K; Xia X; Xie R
    Oncol Res; 2019 Jul; 27(7):801-807. PubMed ID: 30982497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis.
    Zhang X; Song X; Lai Y; Zhu B; Luo J; Yu H; Yu Y
    BMC Cancer; 2021 Apr; 21(1):483. PubMed ID: 33931030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted sequencing of cancer-related genes in nasopharyngeal carcinoma identifies mutations in the TGF-β pathway.
    Chung AK; OuYang CN; Liu H; Chao M; Luo JD; Lee CY; Lu YJ; Chung IC; Chen LC; Wu SM; Tsang NM; Chang KP; Hsu CL; Li HP; Chang YS
    Cancer Med; 2019 Sep; 8(11):5116-5127. PubMed ID: 31328403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.